Experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide considerations for regimen selection and emerging treatment options.
January 25th 2021, 8:00pm
Daratumumab represents an important addition to the armamentarium of care for improving patient outcomes, said Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
January 20th 2021, 9:10pm
Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.
January 20th 2021, 7:15pm
A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.
January 20th 2021, 7:00pm
Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.
January 14th 2021, 9:00pm
A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.
January 12th 2021, 6:16pm
Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).
January 7th 2021, 2:00pm
Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).
January 5th 2021, 8:45pm
Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
December 30th 2020, 5:00am
New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.
December 28th 2020, 1:15pm
Gene-editing therapy in sickle cell disease and advances in multiple myeloma dominated hematology news in 2020.
